Central nervous system involvement in diffuse large B-cell lymphoma
Background: Malignant lymphoma with central nervous system (CNS) involvement has an extremely poor prognosis. We retrospectively studied the risk factors for CNS involvement in patients with diffuse large B-cell lymphoma (DLBCL) treated by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab (R) -CHOP chemotherapy.
Patients and methods: We studied 375 consecutive patients who were newly diagnosed with DLBCL between 1996 and 2006. Patients with primary CNS involvement and patients who received CNS prophylaxis were excluded. All the patients received CHOP (n = 172) or R-CHOP (n = 203) chemotherapy. The following variables were assessed for their potential to predict CNS involvement: gender, age, serum lactate dehydrogenase (LDH) level, performance status, clinical stage, number of extranodal involvements, International Prognostic Index (IPI), bone marrow involvement, presence of a bulky mass, presence of B symptom, and treatment.
Results: CNS involvement was observed in 13 cases (3.5%). In univariate analysis, LDH more than normal range, LDH more than twice as normal range, high IPI, bone marrow involvement, and systemic relapse were the predictors for CNS involvement. In multivariate analysis, no risk factors were detected for CNS involvement. The use of rituximab did not have an impact on CNS involvement.
Conclusions: The incidence of CNS involvement dose not decrease in rituximab-era.
Document Type: Research Article
Affiliations: 1: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama 2: Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka 3: Department of Hematology, Yokosuka City Hospital, Yokosuka 4: Department of Hematology and Immunology, Fujisawa City Hospital, Fujisawa 5: Department of Chemotherapy, Kanagawa Cancer Center, Yokohama, Japan
Publication date: July 1, 2010